Back to Search
Start Over
Striatal glutamate, subcortical structure and clinical response to first-line treatment in first-episode psychosis patients.
- Source :
-
Progress in neuro-psychopharmacology & biological psychiatry [Prog Neuropsychopharmacol Biol Psychiatry] 2022 Mar 08; Vol. 113, pp. 110473. Date of Electronic Publication: 2021 Nov 06. - Publication Year :
- 2022
-
Abstract
- Introduction: Recent studies have observed that patients with treatment-resistant schizophrenia as well as patients with schizophrenia who do not respond within a medication trial exhibit excess activity of the glutamate system. In this study we sought to replicate the within-trial glutamate abnormality and to investigate the potential for structural differences and treatment-induced changes to improve identification of medication responders and non-responders.<br />Methods: We enrolled 48 medication-naïve patients in a 4-week trial of risperidone and classified them retrospectively into responders and non-responders using clinical criteria. Proton magnetic resonance spectroscopy and T <subscript>1</subscript> -weighted structural MRI were acquired pre- and post-treatment to quantify striatal glutamate levels and several measures of subcortical brain structure.<br />Results: Patients were classified as 29 responders and 19 non-responders. Striatal glutamate was higher in the non-responders than responders both pre- and post-treatment (F <subscript>1,39</subscript>  = 7.15, p = .01). Volumetric measures showed a significant group x time interaction (t = 5.163, <1%FDR), and group x time x glutamate interaction (t = 4.23, <15%FDR) were seen in several brain regions. Striatal volumes increased at trend level with treatment in both groups, and a positive association of striatal volumes with glutamate levels was seen in the non-responders.<br />Conclusions: Combining anatomic measures with glutamate levels offers the potential to enhance classification of responders and non-responders to antipsychotic medications as well as to provide mechanistic understanding of the interplay between neuroanatomical and neurochemical changes induced by these medications. Ethical statement The study was approved by the Ethics and Scientific committees of the Instituto Nacional de Neurología y Neurocirugía in Mexico City. All participants over 18 years fully understood and signed the informed consent; in case the patient was under 18 years, informed consent was obtained from both parents. Participants did not receive a stipend.<br /> (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Subjects :
- Adult
Brain metabolism
Female
Humans
Image Processing, Computer-Assisted
Magnetic Resonance Imaging
Male
Proton Magnetic Resonance Spectroscopy
Retrospective Studies
Risperidone pharmacology
Serotonin Antagonists pharmacology
Surveys and Questionnaires
Young Adult
Corpus Striatum drug effects
Corpus Striatum metabolism
Glutamic Acid metabolism
Psychotic Disorders drug therapy
Psychotic Disorders metabolism
Risperidone administration & dosage
Schizophrenia, Treatment-Resistant drug therapy
Schizophrenia, Treatment-Resistant metabolism
Serotonin Antagonists administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1878-4216
- Volume :
- 113
- Database :
- MEDLINE
- Journal :
- Progress in neuro-psychopharmacology & biological psychiatry
- Publication Type :
- Academic Journal
- Accession number :
- 34748864
- Full Text :
- https://doi.org/10.1016/j.pnpbp.2021.110473